Recent advances in treatment for childhood acute lymphoblastic leukaemia (ALL) have significantly increased outcome. High-dose methotrexate (MTX) is the most commonly used regimen during the consolidation period, but the optimal dose remains to be defined. We investigated the usefulness of the MTHFR genotype to increase the MTX dosage in the consolidation phase in 141 childhood ALL patients enrolled in the ALL/SHOP-2005 protocol. We also investigated the pharmacogenetic role of polymorphisms in genes involved in MTX metabolism on therapy-related toxicity and survival. Patients with a favourable MTHFR genotype (normal enzymatic activity) treated with MTX doses of 5 g m À2 had a significantly lower risk of suffering an event than patients with an unfavourable MTHFR genotype (reduced enzymatic activity) that were treated with the classical MTX dose of 3 g m À2 (P ¼ 0.012). Our results indicate that analysis of the MTHFR genotype is a useful tool to optimise MTX therapy in childhood patients with ALL.
Introduction
Acute lymphoblastic leukaemia (ALL) is the most common paediatric cancer, accounting for 25% of all cancers in children. 1 In the last three decades, great progress has been made in diagnosis and outcome, with 5-year event-free survival (EFS) rates of 70-80% and overall cure rates of 80%. 2 Such an improvement in the treatment outcome is largely due to the optimal use of antileukemic agents and the adaptation of treatment to the clinical risk. Nevertheless, 5% of children do not achieve remission and 10-20% of children either do not respond to treatment or relapse. 3 Besides, interruption of treatment due to toxicity may further increase the risk of relapse.
High-dose methotrexate (MTX) is widely used in the treatment of ALL during the consolidation period. Assuming that toxicity induced by this chemotherapeutic regimen can be related to variants in genes involved in MTX metabolism, the identification of these genetic changes could contribute to the individualisation of chemotherapy to reduce the toxicity. 4 The metabolic pathway of MTX is depicted in Figure 1 . The cellular uptake of MTX occurs by passive diffusion, which is dependent on increasing extracellular concentrations of MTX and also on a carrier transport mechanism mediated by reduced folate carrier 1 (RFC1). A common genetic polymorphism, consisting of a G4A transition in exon 1 of the RFC1 gene, which replaces Arg by His, has been associated with higher serum MTX levels and worse prognosis in patients with RFC1 80AA genotype. 5 Once inside the cell, MTX is polyglutamylated by the enzyme folylpolyglutamate synthetase. MTX and its polyglutamates are potent inhibitors of dihydrofolate reductase (DHFR). Moreover, MTX polyglutamates also target thymidylate synthase (TS). Inhibition of these enzymes affects DNA synthesis and cell replication, thereby blocking cell growth.
DHFR catalyses the conversion of dihydrofolate into tetrahydrofolate (THF). Its inhibition therefore depletes reduced forms of THF required in folate homeostasis. Recent studies have investigated the polymorphisms located in the promoter and gene coding regions in ALL paediatric patients. They found an association of the A allele of G308A variation and the *1b haplotype with a lower EFS. This association was more significant in high-risk patients. 6, 7 TS catalyses the nonreversible methylation of deoxyuridine-5-monophosphate to deoxythymidine-5-monophosphate, a precursor for DNA synthesis. Therefore, the inhibition of TS depletes thymidine and damages DNA. The TS gene is polymorphic, with either double (2R) or tri-tandem (3R) repeats of a 28-bp sequence in the promoter region. Homozygous 3R/3R cells over-express TS mRNA compared with homozygous 2R/2R cells. 8, 9 A singlenucleotide polymorphism (SNP) G4C has been described at the 12th nucleotide of the second repeat of the 3R allele, leading to a tri-allelic locus (2R, 3RG and 3RC). This G4C substitution changes a critical residue in the upstream transcription factor E-box consensus element, abolishes upstream transcription factor-1 binding and alters transcriptional activity. 10 ALL children who are homozygous for the 3R allele have been found to have poorer EFS than those with other genotypes. 11, 12 Cyclin D1 (CCND1) can be associated with DHFR and TS regulation at the transcription levels. The transcription factors E2F-1 and DP-1 are released by the action of CCND1, a protein involved in the retinoblastoma protein phosphorylation, provoking an increase in the transcription levels of DHFR and TS. 13 The pharmacogenetic role of the polymorphism A870G in CCND1 has been studied in childhood ALL patients and a lower EFS in homozygous cases for the A allele has been found. 14 As shown in Figure 1 , the 5,10-methylenetetrahydrofolate reductase (MTHFR) catalyses the reduction reaction of 5,10-methylene-THF to 5-methyl-THF. MTHFR C677T and A1298G polymorphisms have been associated with decreased activity of MTHFR and with increased levels of homocysteine. 15, 16 Contradictory results linking these polymorphisms with relapse and toxicity risk in paediatric ALL patients have recently been reviewed. 17 We investigated the pharmacogenetic role of several polymorphisms in genes involved in MTX metabolism. We also studied the usefulness of the MTHFR genotype to individualise high-dose MTX in the consolidation phase of childhood ALL therapy in an attempt to improve outcome without increasing toxicity. Patients were stratified into three risk groups: low, intermediate and high risk according to a score based on age, immunophenotype, white blood cell count, extramedullary involvement, cytogenetic and molecular abnormalities, bone marrow blast cells at day 14 of treatment and presence of minimal residual disease at the end of induction.
Patients and methods

Patients
The treatment protocol of ALL/SHOP-2005, schematised in Figure 2 , consists of an induction and consolidation phase with prophylaxis of central nervous system disease. An early intensification phase is administered in intermediate-risk patients and five intensification blocks are administered in high-risk patients. A 2-year maintenance treatment is established for all patients except for those in the high-risk group who will receive allogeneic haemopoietic stem cell transplantation.
Haematological (leucopenia, anaemia, thrombocytopenia) and non-haematological (hepatic and gastrointestinal) toxicity was graded according to World Health Organization criteria (grades 0-4).
Genotype analyses
The genomic DNA was extracted from blood samples by the salting-out procedure. 18 The genetic markers analysed in the study are shown in Table 1 .
We analysed the two SNPs (C677T and A1298T) in the MTHFR gene, the A80G polymorphism in the RFC1 gene, the A870G polymorphism in the CCND1 gene, as well as the A-317G and the C-680A promoter changes in the DHFR gene using the 48.48 dynamic array chips in the BioMarkt system (Fluidigm, South San Francisco, CA). This technology is designed for the allelic discrimination 5 0 nuclease assay. The samples and the TaqMan SNP genotyping assay mixes were prepared following the manufacturer's instructions (Applied Biosystems, Foster City, CA, USA). The chips were primed in the NanoFlex IFC Controller (Fluidigm). Samples and genotyping assays mixes were then loaded into the inlets of the chips and the chips were returned to the IFC Controller for loading and mixing for 45 min. PCR was performed in the BioMark system (Fluidigm) and the thermal cycling conditions were: an initial step at 50 1C for 2 min and at 95 1C for 10 min, followed by a second step of 40 cycles at 95 1C for 15 s and at 60 1C for 1 min. Finally, the end point fluorescent image data were acquired on the BioMark Real-Time PCR System and analysed using the Fluidigm SNP Genotyping Analysis software (Fluidigm). Normal, heterozygous and homozygous sequenced samples of each polymorphism were included as internal controls. Two additional polymorphisms in the DHFR gene were analysed: (i) C-1610G/T was determined by direct sequence using an ABI PRISM 3100 Genetic Analyzer (Applied Biosystems), and (ii) a 19 bp insertion/deletion was determined by a conventional PCR method. 6 In the TS gene, we analysed the variable number tandem repeat of 28 bp polymorphism and the G4C SNP in the first and second repeats. A DNA fragment was amplified using previously described PCR conditions and primers, 8 and directly sequenced using an ABI PRISM 3100 Genetic Analyzer (Applied Biosystems). TS genotypes of the patients were classified into two groups according to Kawakami and Watanabe 19 : high-expression type (*2/*3G, *3C/*3G and *3G/*3G) and low-expression type (*2/*2, *2/*3C and *3C/*3C). MTHFR genotype/MTX dosage in the consolidation phase According to the treatment protocol, patients with an unfavourable MTHFR genotype (homozygous 677T, homozygous 1298C and compound heterozygous patients) associated with a decreased enzymatic activity were given 3 g m À2 MTX in a 24-h infusion, whereas patients with a favourable MTHFR genotype (heterozygous and wild-type patients) associated with a normal enzymatic activity were given an increased dose of 5 g m À2 MTX.
Statistical analysis
We performed the following statistical analyses to study whether MTX dose during consolidation therapy can be increased without increasing toxicity in patients with a MTHFR genotype associated with a normal enzymatic activity. The w 2 test (univariate analysis) was used to estimate the risk of developing toxicity after therapy in patients with different genotypes. Multivariate logistic regression analysis was used to calculate the adjusted odds ratio and the dependent variable was the degree of toxicity. The multivariate model included the risk groups and the polymorphisms as covariates.
We used the following parameters to study the association between EFS and genotype. EFS was measured from the date of diagnosis to the date of event (recurrence, death or last follow-up). For censored cases, EFS corresponded to the time between diagnosis and the end of follow-up. Survival rates and median survival times were estimated using the Kaplan-Meier method with the log-rank test to determine statistical significance. Cox's regression analysis was used to estimate the hazard ratio (HR) for developing an event in the follow-up period (95% confidence interval). Clinical risk groups and other polymorphisms were included as covariates.
Bonferroni multiple comparison corrections considering four genetic variables has been applied and differences between means were considered statistically significant if the P-value was o0.013.
All analyses were performed by SPSS Statistical Package (SPSS, Chicago, IL, USA).
Results
A total of 141 patients with childhood ALL were treated with ALL/SHOP-2005 protocol according to their risk assessment (see Methods). Their demographic/clinical characteristics are summarised in Table 2. The frequencies of the different alleles defined by the polymorphisms included in the study are shown in Table 1 ; all of them were in Hardy-Weinberg equilibrium.
Two variations in the DHFR gene, A-317G and 19 pb ins/ del, were in linkage disequilibrium (r 2 ¼ 0.956; minor allele frequency ¼ 0.05): alleles with an A residue in the A-317G SNP contained an insertion in the 19 pb ins/del polymorphism, and alleles with a G in the A-317G SNP contained a deletion in the 19 pb ins/del polymorphism. As both variations gave almost the same information for association analysis, from here on, we consider only the role of 19 pb ins/del polymorphism.
Analysis of toxicity in association with the polymorphisms affecting folate metabolism
Only the most severe adverse effects that appeared in any of the three high-dose MTX administrations in the consolidation phase were taken into account. We have previously defined the combination of MTHFR polymorphisms that define the genotypes associated with a decreased enzymatic activity (unfavourable MTHFR genotype) and those associated with a normal activity (favourable MTHFR genotype). 20 The use of this MTHFR genetic classification in the analysis of the toxicities developed by our patients showed that there are two statistically significant associations: (i) between a significant decrease in the number of platelets (o50 Â 10 9 l À1 ) and the presence of a genotype associated with a decreased MTHFR activity (34.3% vs 14.3%; P ¼ 0.014) and (ii) between a high level of serum creatinine (41.26 Â N* mmol l À1 ) and the same MTHFR genotype (18.2 vs 3.9%; P ¼ 0.013).
Analysis of the remaining polymorphisms and their relationship with the development of toxicities has shown that: (i) thrombocytopenia is associated with the genotype ins/ins of the 19 pb ins/del polymorphism in the DHFR gene (36.4 vs 10.9%; P ¼ 0.001) and (ii) grade X2 mucositis was associated with the genotype G/G of the RFC1 gene (25.6 vs 7.4%; P ¼ 0.008).
Multivariate analysis also considered the clinical risk categories as a covariate and showed that only the following associations maintained their statistical significance: thrombocytopenia o50 Â 10 9 l À1 with a genotype associated with a decreased MTHFR activity (P ¼ 0.006, HR: 4.06, confidence interval (CI): 95% 1.5-11.1); thrombocytopenia o50 Â 10 9 l À1 with the G/G genotype of the RFC1 gene (P ¼ 0.02, HR: 3.2, CI: 95% 1.2-8.6) and thrombocytopenia o50 Â 10 9 l À1 with the genotype ins/ins of the 19 pb ins/del polymorphism in the DHFR gene (P ¼ 0.002, HR: 4.7, CI: 95% 1.8-12.6). Severe neutropenia was associated with the C/C genotype in the C-680A SNP of the DHFR gene (P ¼ 0.01, HR: 2.9, CI: 95% 1.3-7.1). The high level of serum creatinine (41.26 Â N* mmol l À1 ) was associated with the MTHFR genotype that determined a decreased enzymatic activity (P ¼ 0.013, HR: 5.5, CI: 95% 1.4-20.9). Finally, the relationship between grade X2 mucositis and the genotype G/G of the RFC1 gene remained significant (P ¼ 0.008, HR: 4.4, GI: 95% 1.4-13.2).
Event-free survival and genotype
In relation to clinical and genetic determinants, the univariate analysis of EFS demonstrated significant differences between patients grouped in accordance with the clinical classification (P ¼ 0.047; Figure 3a) . The MTHFR genotype classified the patients into two groups with significantly different EFS at 48 months (P ¼ 0.012; Figure 3b ). The other genetic markers did not reveal differences. Using the Cox regression model, which includes both clinical and genetic determinants, the clinical classification and the MTHFR genotype retained their independent predictive value (Table 3) . EFS was similar in low-and intermediate-risk cases, whereas it was significantly lower in high-risk patients. Patients with a MTHFR genotype associated with decreased enzyme activity were 4.3 times more at risk to suffer an event than those with a genotype (Figure 3c ).
Discussion
In this study, we found that children with a favourable MTHFR genotype treated with MTX doses of 5 g m À2 develop a similar or, in some cases, less toxicity than those children with an unfavourable genotype that were treated with the classical MTX dose of 3 g m
À2
. An increase in the MTX dose from 3 to 5 g m À2 in the consolidation phase was the most relevant change introduced in the ALL/SHOP-2005 protocol used in the present study with respect to the previous ALL/SHOP protocols. 21 As there are data that emphasise the pharmacogenetic role of the MTHFR genotype in treatments including MTX, we decided to increase the MTX dose only in those patients with a MTHFR genotype associated with normal enzymatic activity. In the group of patients with a genotype associated with decreased MTHFR activity, we administered the same dose of MTX as that used in the previous ALL/SHOP protocols: 3 g m À2 in a 24-h infusion. We also found that ALL children with a favourable MTHFR genotype treated with MTX doses of 5 g m À2 had significantly better EFS at 48 months. Other studies have also linked the MTHFR genotype with outcome in this setting. In a cohort of 201 children treated with different ALL protocols, Krajinovic et al. 22 showed that patients with the MTHFR T677A1298 haplotype had a poorer EFS. In a trial of 520 patients treated on CCG-1891 study, Aplenc et al. 23 found that the MTHFR C677T polymorphism was associated with relapse but the MTHFR A1298G polymorphism was not. More recently, Pietrzyk et al. 24 examined the relation between the MTHFR gene and mortality risk in children treated with the ALL IC BFM 2002 protocol, and found that the MTHFR 677TT genotype was fourfold more frequent in the children who died (31/389).
The main adverse effect of MTX is nephrotoxicity. MTX and its metabolite 7-hydroxy-MTX precipitate in the renal tubules causing renal dysfunction. 25 This, in turn, may delay MTX excretion and maintain high plasma MTX levels, increasing toxicity even further. Even though patients are monitored and precautions such as hydration, alkalinisation of urine and leucovorin rescue are taken to prevent renal toxicity, nephrotoxicity continues to occur in some patients. Turello et al. 26 recently reported the case of a child with lymphoblastic T-cell lymphoma and homozygous for MTHFR genotype who had high levels of serum creatinine after MTX treatment. Gammon et al. 27 reported the case of an adult patient with large B-cell lymphoma who was heterozygous for this genotype and also had high creatinine levels. The authors considered that toxicity appeared because of a marked folate depletion caused by the combined effect of MTX and the MTHFR genotype. Our results support these findings in that patients with the MTHFR genotype associated with a decreased enzymatic activity had statistically significant higher levels of creatinine in serum, despite of the reduced high-dose MTX (3 g m
). Haematological toxicities, particularly thrombocytopenia, may also occur because of persistently high serum MTX concentrations. A recent study in patients treated for childhood ALL and non-Hodgkin lymphoma with high-dose MTX (5 g m À2 ) reported that subjects with MTHFR polymorphism for A1298C had significantly higher MTX levels at 48 h and presented more haematological toxicities, including thrombocytopenia (P ¼ 0.0001). 28 Our results also showed a significant decrease in the number of platelets in patients with a MTHFR genotype associated with a decreased enzymatic activity.
Data concerning the involvement of polymorphisms in other genes in the MTX pathway are scarce and in some cases, contradictory. We have found the following phenotype-genotype associations: (i) ins/ins of the 19 pb ins/del polymorphism in the DHFR gene with thrombocytopenia, (ii) the genotype G/G of the RFC1 gene with mucositis grade X2. Further prospective studies with larger number of cases are needed to establish the clinical usefulness of these findings.
In summary, our results show that the dose of MTX can be increased up to 5 g m À2 in the consolidation phase of ALL treatment without increasing toxicity in patients with a favourable MTHFR genotype. These findings therefore indicate that analysis of the MTHFR genotype is a useful tool to optimise MTX therapy in childhood patients with ALL. The application of 'risk-adapted' therapy represents an important advance in the treatment of childhood ALL. The identification of pharmacogenetic markers of interest in antileukemic treatments will provide refinement in risk classifications schemes allowing optimal treatment selection and dose individualisation in ALL children. 
